Katherine L. Pogue-Geile

TL;DR: Testing the hypothesis that molecular subtypes of colon cancer would be associated with differential prognosis and benefit from oxaliplatin added to fluorouracil plus leucovorin therapy found patients with stemlike tumors may be appropriate for clinical trials testing experimental therapies.

TL;DR: Adding palbociclib to letrozole significantly enhanced the suppression of malignant cell proliferation (Ki-67) in primary ER-positive BC, but did not increase the clinical response rate over 14 weeks, which was possibly related to a concurrent reduction in apoptosis.

TL;DR: Gen expression profiling of paraffin-embedded tumors from National Surgical Adjuvant Breast and Bowel Project trials that tested the worth of tamoxifen as an adjuvant systemic therapy and as a preventive agent suggest that low-level expression of ESR1 is a determinant of tamxifen resistance in ER-positive breast cancer.

TL;DR: PIK3CA and PAM50 intrinsic subtypes were not predictive biomarkers for adjuvant trastuzumab in NSABP B-31, suggesting that results from the metastatic and neoadjuvant setting may not be always applicable to the adjuant setting.

TL;DR: A gene expression-based predictive model for degree of benefit from trastuzumab was developed and demonstrated that HER2-negative tumors belong to the moderate benefit group, thus providing justification for testing trastzumab in Her2- negative patients (NSABP B-47).